U.S. Food and Drug Administration approved Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Veozah is the first neurokinin 3 (NK3) receptor antagonist approved by the FDA to treat moderate to severe hot flashes from menopause. It works by binding to and blocking the activities of the NK3 receptor, which plays a role in the brain\u2019s regulation of body temperature. Menopause is a normal, natural change in a woman\u2019s life when her period stops, usually occurring between ages 45 and 55. Menopause is often referred to as \u201cthe change of life\u201d or \u201cthe change.\u201d<\/p>\n
If VEOZAH (fezolinetant) tablets\u00a0<\/strong>are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n Note:<\/strong><\/em> VEOZAH is a prescription medicine used\u00a0to reduce moderate to severe vasomotor symptoms due to menopause<\/b>. VEOZAH is not a hormone. Vasomotor symptoms are the feelings of warmth in the face, neck, and chest, or sudden intense feelings of heat and sweating (\u201chot flashes\u201d or \u201chot flushes\u201d).<\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"VEOZAHTM (fezolinetant) tablets, for oral use Initial U.S. Approval: 2023<\/h2>\n